Redx Pharma (LON:REDX) Stock Crosses Below Fifty Day Moving Average of $15.52

Redx Pharma Plc (LON:REDX)’s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 15.52 ($0.19) and traded as low as GBX 8.02 ($0.10). Redx Pharma shares last traded at GBX 10 ($0.12), with a volume of 469,387 shares traded.

Redx Pharma Price Performance

The business has a 50 day moving average of GBX 15.52 and a 200-day moving average of GBX 20.53. The stock has a market cap of £38.90 million, a PE ratio of -100.00 and a beta of -0.53. The company has a current ratio of 1.11, a quick ratio of 1.93 and a debt-to-equity ratio of 527.00.

Insider Buying and Selling

In other news, insider Lisa Anson purchased 115,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The shares were purchased at an average price of GBX 9 ($0.11) per share, for a total transaction of £10,350 ($12,784.09). 18.23% of the stock is currently owned by company insiders.

Redx Pharma Company Profile

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.